Oriola Oyj Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
February 16, 2024 at 01:30 am EST
Share
Oriola Oyj reported earnings results for the fourth quarter and full year ended December 31, 2023. For the fourth quarter, the company reported sales was EUR 386.6 million compared to EUR 380 million a year ago. Net loss was EUR 2.8 million compared to EUR 37.9 million a year ago. Basic loss per share from continuing operations was EUR 0.02 compared to EUR 0.04 a year ago. Diluted loss per share from continuing operations was EUR 0.02 compared to EUR 0.04 a year ago. Basic loss per share was EUR 0.02 compared to EUR 0.21 a year ago. Diluted loss per share was EUR 0.02 compared to EUR 0.21 a year ago.
For the full year, sales was EUR 1,493.8 million compared to EUR 1,539.1 million a year ago. Net loss was EUR 20.7 million compared to EUR 2.4 million a year ago. Basic loss per share from continuing operations was EUR 0.11 compared to basic earnings per share from continuing operations of EUR 0.03 a year ago. Diluted loss per share from continuing operations was EUR 0.11 compared to diluted earnings per share from continuing operations of EUR 0.03 a year ago. Basic loss per share was EUR 0.11 compared to EUR 0.01 a year ago. Diluted loss per share was EUR 0.11 compared to EUR 0.01 a year ago.
Oriola Oyj, formerly known as Oriola-KD Corporation Oyj, is a Finland-based company active in the pharmaceutical sector. The Company is engaged in the retail and wholesale of pharmaceuticals, acting as a channel between pharmaceutical manufacturers and consumers, primarily in Finland and Sweden. The Company's reporting segments are Consumer, Services, and Healthcare. Through its own pharmacies, the Company provides consumers with not only medicines and pharmaceutical advice but also a selection of healthcare consumer products and customer service. The Company is active through a number of subsidiaries located throughout Europe, including PharmaService OY, Oriola AB, Oriola Oyj, Farenta Oy, Kronans Droghandel Apotek AB and Svensk dos AB.
ORIOLA OYJ 
